02/01/2013
Search
Sequence analysis of mutations and translocations across breast cancer subtypes.
AuthorsBanerji S, et al. Show all Journal
Nature. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154.
Affiliation
The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Comment in
Nat Rev Cancer. 2012 Aug;12(8):507.
Nature. 2012 Jun 21;486(7403):328-9.
Abstract
Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.
PMID 22722202 [PubMed - indexed for MEDLINE]
Full text: Nature Publishing Group
Related CitationsShow all
Comprehensive molecular portraits of human breast tumours.
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
Standard PubMedNIH/NLM NCBI Copyright Help
